News|Articles|June 1, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-06-07-2016
  • Volume 11
  • Issue 6

ICP-MS Designed to Lower Operating Costs

The ICPMS-2030 inductively coupled plasma mass spectrometer from Shimadzu Scientific Instruments is designed for efficient, sensitive trace element analysis.

The ICPMS-2030 inductively coupled plasma mass spectrometer from Shimadzu Scientific Instruments features analysis assistant functions and proprietary cost-reducing capabilities, for efficient, sensitive trace element analysis, the company reports. 

The system’s Development Assistant automatically selects the optimal mass and internal standard for the target elements and suggests concentration ranges for calibration curves. The Diagnosis Assistant identifies the presence or absence of mass interference based on qualitative analysis.

A Mini-Torch system reduces the amount of argon gas needed to generate plasma; ECO mode minimizes the flow rate and power consumption during standby. The instrument can operate on 99.95% purity argon gas, instead of the more expensive 99.999% argon gas generally used.

The instrument suppresses molecular interference through optimization of the collision cell and internal ion path geometry. Benefits include nine orders of magnitude dynamic range with a secondary electron multiplier, enabling analysis of major and trace-level components in the same sample and an off-axis lens configuration that eliminates photoelectric effects, optimizing the instrument’s compatibility with laser ablation systems.

Source: Shimadzu Scientific Instruments

 

 


Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.